Robert Dorr Selected Research

4- imino- 1,3- diazabicyclo(3.1.0)hexan- 2- one

10/2010	A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
8/2010	A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
5/2007	Phase I trial of imexon in patients with advanced malignancy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert Dorr Research Topics

Disease

2	Melanoma (Melanoma, Malignant) 08/2010 - 08/2005
2	Neoplasms (Cancer) 05/2007 - 08/2005
1	Prostatic Neoplasms (Prostate Cancer) 10/2010
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2010
1	Granuloma 02/2003

Drug/Important Bio-Agent (IBA)

3	4- imino- 1,3- diazabicyclo(3.1.0)hexan- 2- oneIBA 10/2010 - 05/2007
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2010
1	Docetaxel (Taxotere)FDA Link 10/2010
1	Dacarbazine (DIC)FDA LinkGeneric 08/2010
1	penicillamine benzyl esterIBA 08/2005
1	EstersIBA 08/2005
1	Penicillamine (Cuprimine)FDA Link 08/2005
1	PolymersIBA 08/2005
1	D-Penicillamine (2,5)- EnkephalinIBA 02/2003

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 08/2010
1	Injections 08/2005
1	Catheters 02/2003